The estimated Net Worth of Brian Joseph Lynch is at least $7.8 Million dollars as of 4 December 2023. Mr. Lynch owns over 2,800 units of Madrigal Pharmaceuticals Inc stock worth over $3,728,233 and over the last 5 years he sold MDGL stock worth over $0. In addition, he makes $4,068,640 as Senior Vice President und General Counsel at Madrigal Pharmaceuticals Inc.
Sign up
Mr. Lynch MDGL stock SEC Form 4 insiders trading
Brian has made over 4 trades of the Madrigal Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,800 units of MDGL stock worth $233,184 on 4 December 2023.
The largest trade he's ever made was exercising 13,000 units of Madrigal Pharmaceuticals Inc stock on 3 January 2023 worth over $1,193,270. On average, Brian trades about 2,483 units every 29 days since 2020. As of 4 December 2023 he still owns at least 16,001 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Mr. Lynch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Lynch biography
Brian J. Lynch serves as Senior Vice President, General Counsel of the Company. Brian has over 33 years of legal experience, including over 28 years in private practice. Brian has served as a Partner in leading law firms headquartered in Philadelphia (Morgan, Lewis & Bockius and Drinker Biddle & Reath), Washington, DC (Hogan Lovells) and Silicon Valley (Cooley), and a significant portion of his private practice experience was focused on serving life sciences companies. In addition to his law firm experience, Mr. Lynch served as our Consulting General Counsel (from July of 2018 through February of 2019) and in public service in Washington, DC (from 1987 -1990) in the Division of Corporation Finance at the Securities and Exchange Commission.
What is the salary of Brian Lynch?
As the Senior Vice President und General Counsel of Madrigal Pharmaceuticals Inc, the total compensation of Brian Lynch at Madrigal Pharmaceuticals Inc is $4,068,640. There are 2 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.
How old is Brian Lynch?
Brian Lynch is 58, he's been the Senior Vice President und General Counsel of Madrigal Pharmaceuticals Inc since 2019. There are 11 older and 5 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
What's Brian Lynch's mailing address?
Brian's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN, PA, 19428.
Insiders trading at Madrigal Pharmaceuticals Inc
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman und Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
What does Madrigal Pharmaceuticals Inc do?
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
What does Madrigal Pharmaceuticals Inc's logo look like?
Complete history of Mr. Lynch stock trades at Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc executives and stock owners
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Paul Friedman,
Chairman of the Board, Chief Executive Officer -
Rebecca Taub,
President of Research and Development, Chief Medical Officer, Director -
Brian Lynch,
Senior Vice President, General Counsel -
Marc Schneebaum,
Chief Financial Officer, Senior Vice President -
James Daly,
Independent Director -
Dr. Paul A. Friedman M.D.,
Chairman & CEO -
Dr. Rebecca A. Taub M.D.,
Founder, Chief Medical Officer, Pres of R&D and Director -
Remy Sukhija,
Sr. VP & Chief Commercial Officer -
Brian J. Lynch J.D.,
Sr. VP & Gen. Counsel -
Brian J. Lynch,
Sr. VP & Gen. Counsel -
Kenneth Bate,
Independent Director -
Richard Levy,
Independent Director -
Keith Gollust,
Independent Director -
David Milligan,
Independent Director -
Frederick Craves,
Lead Independent Director -
Remy Sukhija,
Senior Vice President, Chief Commercial Officer -
Edward Chiang,
Sr. VP of Clinical & Technical Operations -
Dr. Stephen Dodge M.B.A., Pharm.D.,
Sr. VP & Global Head of Medical Affairs -
Dr. Robert E. Waltermire Ph.D.,
Chief Pharmaceutical Devel. Officer -
Thomas W. Hare,
Sr. VP of Clinical Management -
Dr. Kianoush Motesharei Ph.d.,
Sr. VP of Bus. & Corp. Devel. -
Alex G. Howarth,
Chief Financial Officer -
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp667, L.P.B...,
-
Chen Schor,
Former President and CEO -
Wendy E Rieder,
Former SVP, Gen. Counsel -
City Capital Llc Bay,
Director -
City Capital Llc Bay City C...,
-
Alex G. Howarth,
Chief Financial Officer -
Robert E. Waltermire,
Senior VP, Chief Pharma Dev. -
Bros. Advisors Lp Baker,
-
Shannon T Kelley,
General Counsel -
William John Sibold,
President and CEO -
Carole Huntsman,
Chief Commercial Officer -
Fred B Craves,